GlassScriptPhysician profile
Kellie D West
NPI 1215347182
$6,832.74
in general payments reported to CMS, 2019-2025
55 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $643 · 2023: $1,648 · 2024: $2,240 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,284 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,284.00 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $868.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $632.68 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $495.33 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $366.04 | 2021-2025 | |
| Daiichi Sankyo INC. | $345.11 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $337.54 | 2022-2025 | Calquence, Imfinzi, Enhertu |
| Celgene Corporation | $297.78 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $261.94 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Abbvie INC. | $195.49 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.34 | 2021-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Exelixis INC. | $166.37 | 2022-2025 | Cabometyx |
| Genzyme Corporation | $164.85 | 2021-2025 | |
| Eisai INC. | $147.50 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $138.28 | 2022-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $136.80 | 2021-2024 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $133.22 | 2021-2024 | Brukinsa |
| Incyte Corporation | $125.63 | 2023-2024 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $104.92 | 2023-2025 | Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $101.70 | 2023-2025 | Somatuline Depot, Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $98.45 | 2021-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $96.82 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Amgen INC. | $89.14 | 2021-2023 | Kyprolis, Blincyto |
| Karyopharm Therapeutics INC. | $82.53 | 2021-2024 | Xpovio |
| Gilead Sciences, INC. | $80.09 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $79.63 | 2023-2024 | Nerlynx |
| Lilly USA, LLC | $76.06 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $73.69 | 2022-2025 | Gazyva, Lunsumio, Polivy |
| Seagen INC. | $68.55 | 2022-2023 | Adcetris, Tukysa |
| Emd Serono, INC. | $66.83 | 2021-2025 | Bavencio |
| Astellas Pharma US INC | $62.12 | 2021-2025 | Xtandi, Vyloy |
| Array Biopharma INC | $48.89 | 2025 | Lorbrena, Braftovi, Mektovi |
| Alnylam Pharmaceuticals INC. | $46.81 | 2024-2025 | Givlaari |
| Aveo Pharmaceuticals, INC. | $37.90 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.10 | 2023-2024 | Gilotrif |
| Genmab U.S., INC. | $35.74 | 2024 | Tivdak, Epkinly |
| Mirati Therapeutics, INC. | $35.59 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $34.37 | 2023-2024 | Cosela, Monoferric |
| Servier Pharmaceuticals LLC | $34.17 | 2024 | |
| Beone Medicines USA, INC. | $32.04 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $31.52 | 2021-2024 | |
| Stemline Therapeutics INC. | $30.99 | 2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $29.57 | 2024 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $27.88 | 2021-2023 | Rezlidhia, Tavalisse |
| Menarini Silicon Biosystems, INC. | $25.19 | 2025 | |
| Veracyte, INC. | $24.64 | 2023 | |
| Sobi, INC | $23.29 | 2024 | |
| Kyowa Kirin, INC. | $20.97 | 2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $20.12 | 2024 | Libtayo |
| Apellis Pharmaceuticals, INC. | $19.00 | 2024 | Empaveli |
| Blueprint Medicines Corporation | $15.39 | 2022 | |
| Acrotech Biopharma INC. | $15.13 | 2024 | Beleodaq |
| Cumberland Pharmaceuticals, INC. | $13.75 | 2025 | Sancuso |
| Dova Pharmaceuticals | $13.36 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.